Two Sigma Advisers LP Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Two Sigma Advisers LP lifted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 333.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 471,100 shares of the medical research company's stock after buying an additional 362,500 shares during the quarter. Two Sigma Advisers LP owned approximately 0.26% of IQVIA worth $92,576,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of IQV. Norges Bank purchased a new stake in shares of IQVIA in the fourth quarter worth about $336,041,000. Raymond James Financial Inc. purchased a new stake in shares of IQVIA in the fourth quarter worth about $236,120,000. American Century Companies Inc. boosted its stake in shares of IQVIA by 396.0% in the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after buying an additional 905,960 shares during the last quarter. Invesco Ltd. boosted its stake in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after buying an additional 712,958 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 0.4%

NYSE IQV traded up $0.61 during trading on Thursday, reaching $137.90. 3,034,505 shares of the company's stock were exchanged, compared to its average volume of 1,551,125. The stock has a market cap of $23.86 billion, a P/E ratio of 18.39, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a 50 day moving average price of $157.30 and a two-hundred day moving average price of $184.65. IQVIA Holdings Inc. has a 1 year low of $135.77 and a 1 year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter in the previous year, the firm earned $2.54 earnings per share. The business's revenue was up 2.5% compared to the same quarter last year. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Mizuho lowered their price target on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Wall Street Zen downgraded IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Finally, Barclays reduced their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $228.14.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.